Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 25

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 25
---
for payment of the net proceeds to us. Sales of our shares of our Common Stock as contemplated
in this prospectus supplement and the accompanying prospectus
will be settled through the facilities of The
Depository Trust Company or by such other means
as we and Dawson James may agree upon. There is no arrangement
for funds to be received in an escrow, trust or similar arrangement.

We
will pay Dawson James in cash, upon each
sale of shares of our Common Stock pursuant to the Sales
Agreement, a commission of 3.0% of the gross proceeds from each sale of shares. Because
there is no minimum offering amount required as
a condition to this offering,
the actual total public offering amount, sales commissions
and proceeds to us, if any, are
not determinable at this time. Pursuant to the
terms of the Sales Agreement, we agreed to reimburse Dawson James
for its out-of-pocket expenses (including but not limited to the reasonable and documented fees and expenses of its
legal counsel) reasonably incurred
in connection with entering into the transactions
contemplated by the Sales Agreement in an amount not to exceed
$50,000 in the aggregate, in addition to up to
a maximum of $10,000 per year for due diligence
update sessions conducted in connection with
each such date the Company files its quarterly
reports on Form 10-Q and annual report on Form 10-K, for Dawson James counsel’s
fees and any incidental expenses to be reimbursed by us. We
will report at least quarterly the number of shares
of our Common Stock sold
through Dawson James under the Sales Agreement, the net
proceeds to us and the compensation paid by us
to Dawson James in connection with the sales of shares of our Common Stock.

We
have agreed in the Sales Agreement to provide indemnification and
contribution to Dawson James against certain liabilities,
including liabilities under the SecuritiesAct.

The offering
of our shares of our Common Stock pursuant to
the Sales Agreement will terminate upon the
earlier of the sale of all of the shares of our Common Stock provided for in this prospectus
supplement or termination of the SalesAgreement
as permitted therein.

To
the extent required by Regulation M, Dawson James
will not engage in any market making
activities involving our Common Stock while the
offering is ongoing under this prospectus supplement.

<div align='center'>S-17</div>

This prospectus supplement and
the